Mdxhealth Sa Stock Price, News & Analysis

MDxHealth, a precision diagnostics company listed on NASDAQ (MDXH), has scheduled the release of its first quarter 2025 financial results for May 14, 2025, after market close. The company will host a conference call and webcast at 4:30pm ET / 22:30 CET on the same day.

CEO Michael K. McGarrity and CFO Ron Kalfus will lead the presentation. Investors can join via multiple regional dial-in numbers:

• United States: 1-844-825-9789
• Belgium: 0800 38 961
• Netherlands: 0800 94 94 506
• United Kingdom: 0808 238 9064

Participants should access the webcast 15 minutes before the start time using Conference ID 10199102. A replay will be available on the company's website after the live call.

MDxHealth (NASDAQ: MDXH) reported strong Q4 and full-year 2024 financial results, with 28% revenue growth in both Q4 ($24.7 million) and full-year ($90.0 million). Q4 highlights include a 68% improvement in adjusted EBITDA to ($1.4) million and significant test volume increases: tissue-based tests up 50% and liquid-based tests up 10%.

Q4 gross profit increased 22% to $15.5 million with margins at 62.7%, while operating expenses rose 6% to $20.1 million. Net loss decreased 36% to $6.8 million. For full-year 2024, gross profit grew 26% to $55.1 million with 61.2% margins, and net loss improved 12% to $38.1 million.

The company maintains its 2025 revenue guidance of $108-110 million and expects to achieve adjusted EBITDA profitability in H1 2025. Year-end cash position stands at $46.8 million.

MDxHealth SA (NASDAQ: MDXH) has announced it will release its Q4 and full year 2024 financial results after market close on February 26, 2025. The company will host a conference call and webcast at 4:30pm ET / 22:30 CET on the same day.

The conference call will feature CEO Michael K. McGarrity and CFO Ron Kalfus, with dial-in numbers provided for the United States, Belgium, The Netherlands, and the United Kingdom. A webcast replay will be available on the company's website following the live call.

MDxHealth (NASDAQ: MDXH) reported preliminary Q4 and full-year 2024 revenues of $24.7M and $90.0M respectively, showing 28% year-over-year growth for both periods. The company's Q4 performance included 11,789 tissue-based units (+50%) and 12,036 liquid-based units (+10%). For the full year 2024, they billed 41,586 tissue-based units (+31%) and 45,700 liquid-based units (+28%).

The company ended 2024 with a cash balance of $46.8 million and issued 2025 revenue guidance of $108-110 million, projecting 20-22% year-over-year growth. MDxHealth also confirmed its expectation to achieve adjusted EBITDA profitability in the first half of 2025.

MDxHealth (NASDAQ: MDXH) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York City, scheduled for December 3-5, 2024. CEO Michael K. McGarrity will engage in a fireside discussion on Wednesday, December 4, from 3:00-3:25 pm ET. The discussion will be available via live webcast, accessible through the company's investor page, with replays available for 60 days following the event.

MDxHealth reported strong Q3 2024 results with revenue reaching $23.3 million, up 21% year-over-year. The company raised its 2024 revenue guidance to $87-89 million, representing 25% growth. Test volumes showed significant increases with tissue-based tests up 36% and liquid-based tests up 24%. The company strengthened its balance sheet through a $40 million equity offering, resulting in pro-forma cash of $53.5 million. Despite revenue growth, operating loss increased 34% to $6.1 million, and net loss rose 11% to $11.2 million. The company expects to turn adjusted EBITDA positive in first half of 2025.

MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, has announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. The company will host a conference call with live Q&A on the same day at 4:30pm ET / 22:30 CET.

The conference call will feature Michael K. McGarrity, Chief Executive Officer, and Ron Kalfus, Chief Financial Officer. Interested parties can access the call through various dial-in numbers provided for different countries or via a webcast link. A replay of the webcast will be available on the company's website following the conclusion of the live call.

MDxHealth SA (NASDAQ: MDXH) has announced the pricing of a registered public offering of 20,000,000 ordinary shares at $2.00 per share, aiming to raise $40.0 million in gross proceeds. The offering includes a strategic partner purchasing 1,500,000 shares directly from the company. MDxHealth has granted underwriters an option to purchase up to an additional 2,775,000 shares. The closing is expected on September 27, 2024.

The company plans to use the net proceeds for general corporate and working capital purposes, including funding product development and commercial activities. TD Cowen and William Blair are acting as joint book-running managers, with BTIG, and Lake Street Capital Markets as passive bookrunners for the offering.

MDxHealth SA (NASDAQ: MDXH) has announced the launch of a proposed offering of $40.0 million of ordinary shares in a registered public offering. The company plans to grant underwriters a 30-day option to purchase up to 15% additional ordinary shares. TD Cowen and William Blair are acting as joint book-running managers for the offering.

The offering is subject to market conditions, with no assurance of completion or final terms. A preliminary prospectus supplement has been filed with the SEC. The shares are being offered pursuant to a previously filed and effective registration statement. This announcement does not constitute an offer to sell or a solicitation of an offer to buy securities.